102 related articles for article (PubMed ID: 10522697)
21. Antagonist properties of eliprodil and other NMDA receptor antagonists at rat NR1A/NR2A and NR1A/NR2B receptors expressed in Xenopus oocytes.
Avenet P; Léonardon J; Besnard F; Graham D; Depoortere H; Scatton B
Neurosci Lett; 1997 Feb; 223(2):133-6. PubMed ID: 9089691
[TBL] [Abstract][Full Text] [Related]
22. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Mov Disord; 2006 Jan; 21(1):9-17. PubMed ID: 16127720
[TBL] [Abstract][Full Text] [Related]
23. Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
Song L; Zhang Z; Hu R; Cheng J; Li L; Fan Q; Wu N; Gan J; Zhou M; Liu Z
Drug Des Devel Ther; 2016; 10():547-55. PubMed ID: 26893543
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[(11)C]one, as a potent NR(1A)/2B subtype selective NMDA PET radiotracer.
Roger G; Lagnel B; Besret L; Bramoullé Y; Coulon C; Ottaviani M; Kassiou M; Bottlaender M; Valette H; Dollé F
Bioorg Med Chem; 2003 Dec; 11(24):5401-8. PubMed ID: 14642584
[TBL] [Abstract][Full Text] [Related]
25. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
[TBL] [Abstract][Full Text] [Related]
26. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
Marin C; Jimenez A; Bonastre M; Chase TN; Tolosa E
Synapse; 2000 Jun; 36(4):267-74. PubMed ID: 10819904
[TBL] [Abstract][Full Text] [Related]
27. Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition.
Whittemore ER; Ilyin VI; Woodward RM
J Pharmacol Exp Ther; 1997 Jul; 282(1):326-38. PubMed ID: 9223571
[TBL] [Abstract][Full Text] [Related]
28. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Savola JM; Hill M; Engstrom M; Merivuori H; Wurster S; McGuire SG; Fox SH; Crossman AR; Brotchie JM
Mov Disord; 2003 Aug; 18(8):872-83. PubMed ID: 12889076
[TBL] [Abstract][Full Text] [Related]
29. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
Hadj Tahar A; Grégoire L; Darré A; Bélanger N; Meltzer L; Bédard PJ
Neurobiol Dis; 2004 Mar; 15(2):171-6. PubMed ID: 15006686
[TBL] [Abstract][Full Text] [Related]
30. Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
Maranis S; Stamatis D; Tsironis C; Konitsiotis S
Eur J Pharmacol; 2012 May; 683(1-3):71-7. PubMed ID: 22410193
[TBL] [Abstract][Full Text] [Related]
31. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.
Berlin M; Ting PC; Vaccaro WD; Aslanian R; McCormick KD; Lee JF; Albanese MM; Mutahi MW; Piwinski JJ; Shih NY; Duguma L; Solomon DM; Zhou W; Sher R; Favreau L; Bryant M; Korfmacher WA; Nardo C; West RE; Anthes JC; Williams SM; Wu RL; Susan She H; Rivelli MA; Corboz MR; Hey JA
Bioorg Med Chem Lett; 2006 Feb; 16(4):989-94. PubMed ID: 16297617
[TBL] [Abstract][Full Text] [Related]
32. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
Huot P; Johnston TH; Koprich JB; Espinosa MC; Reyes MG; Fox SH; Brotchie JM
Behav Pharmacol; 2015 Feb; 26(1-2):101-8. PubMed ID: 25303957
[TBL] [Abstract][Full Text] [Related]
33. Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes.
Avenet P; Léonardon J; Besnard F; Graham D; Frost J; Depoortere H; Langer SZ; Scatton B
Eur J Pharmacol; 1996 Jan; 296(2):209-13. PubMed ID: 8838458
[TBL] [Abstract][Full Text] [Related]
34. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
[TBL] [Abstract][Full Text] [Related]
35. Subtype-selective antagonism of NMDA receptors by nylidrin.
Whittemore ER; Ilyin VI; Konkoy CS; Woodward RM
Eur J Pharmacol; 1997 Oct; 337(2-3):197-208. PubMed ID: 9430414
[TBL] [Abstract][Full Text] [Related]
36. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
Mela F; Millan MJ; Brocco M; Morari M
Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
[TBL] [Abstract][Full Text] [Related]
37. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
Dunah AW; Wang Y; Yasuda RP; Kameyama K; Huganir RL; Wolfe BB; Standaert DG
Mol Pharmacol; 2000 Feb; 57(2):342-52. PubMed ID: 10648644
[TBL] [Abstract][Full Text] [Related]
38. The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Gutiérrez-Valdez AL; García-Ruiz R; Anaya-Martínez V; Torres-Esquivel C; Espinosa-Villanueva J; Reynoso-Erazo L; Tron-Alvarez R; Aley-Medina P; Sánchez-Betancourt J; Montiel-Flores E; Avila-Costa MR
Behav Pharmacol; 2013 Dec; 24(8):640-52. PubMed ID: 24196024
[TBL] [Abstract][Full Text] [Related]
39. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
Wessell RH; Ahmed SM; Menniti FS; Dunbar GL; Chase TN; Oh JD
Neuropharmacology; 2004 Aug; 47(2):184-94. PubMed ID: 15223297
[TBL] [Abstract][Full Text] [Related]
40. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol.
Ilyin VI; Whittemore ER; Guastella J; Weber E; Woodward RM
Mol Pharmacol; 1996 Dec; 50(6):1541-50. PubMed ID: 8967976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
